GUIDEPOINT INSIGHTS ASH 2022 COVERAGE

Join us, December 10th-13th, as Guidepoint Insights hosts 40+ in-person and virtual events at the American Society of Hematology (ASH) 2022 Conference featuring KOLs who will dive deeper into clinical updates on major disease sites and research areas (live event only, no transcript).

Dates:
Saturday, December 10, 2022 – Tuesday, December 13, 2022

Venue:
The Higgins Hotel New Orleans, 1000 Magazine St, New Orleans, LA 70130

Hybrid Group Meetings

Please select the group meetings you would like to participate in by completing the form below and clicking “submit” at the bottom of the page.

 

    Saturday, December 10th
    (60-Minute Group Meetings - Live Event Only, No Transcript)
    10:00 AM ET (9:00 AM CT) - Ben Samelson-Jones // In-Person
    Hemophilia | Assistant Professor of Pediatrics at University of Pennsylvania
    10:00 AM ET (9:00 AM CT) - Elisabet Manasanch // Virtual
    Multiple Myeloma | Associate Professor at University of Texas MD Anderson Cancer Center
    11:00 AM ET (10:00 AM CT) - Izidore Lossos // In-Person
    Lymphomas | Professor of Medicine at University of Miami
    11:00 AM ET (10:00 AM CT) - Bradley Hunter // Virtual
    Cell Therapies | Director of Immune Effector Cell Therapy and Attending Physician for Bone Marrow Transplant & Medical Oncology at Intermountain Health Care Inc.
    12:00 PM ET (11:00 AM CT) - Sherif Badawy // In-Person
    Non-Malignant Hematology | Associate Professor in the Department of Pediatrics at Northwestern University Feinberg School of Medicine
    12:00 PM ET (11:00 AM CT) - Ashwin Kishtagari // Virtual
    Myelofibrosis | Leukemias | Assistant Professor of Medicine at Vanderbilt University
    1:00 PM ET (12:00 PM CT) - Charles Craddock // In-Person
    Cell Therapies | Leukemias | Physician at University of Birmingham
    1:00 PM ET (12:00 PM CT) - Akshay Sharma // In-Person
    Non-Malignant Hem Transplant | Cell Therapies | Instructor and Research Associate at St. Jude Children's Research Hospital Inc.
    1:00 PM ET (12:00 PM CT) - Muhamed Baljevic // Virtual
    AML and Myelomas | Disease Team Lead, Plasma Cell Dyscrasias and Lymphomas at Vanderbilt University Medical Center
    2:00 PM ET (1:00 PM CT) - Marco Davila // Virtual
    CAR-Ts | Vice Chair for Cellular Therapies at Roswell Park Cancer Insitute
    2:00 PM ET (1:00 PM CT) - Mazyar Shadman // In-Person
    Lymphomas | Associate Professor at University of Washington
    3:00 PM ET (2:00 PM CT) - Vivien Sheehan // In-Person
    Sickle Cell | Director of Translational Sickle Cell Research, Associate Professor of Pediatrics at Emory University
    3:00 PM ET (2:00 PM CT) - David Sallman // In-Person
    AML & MDS | Assistant Member at H. Lee Moffitt Cancer Center & Research Institute Inc.
    4:00 PM ET (3:00 PM CT) - Yi-Bin Chen // In-Person
    Conditioning/AML | Physician at The General Hospital Corporation
    4:00 PM ET (3:00 PM CT) - Ran Reshef // In-Person
    Cell Therapy | Director of Translational Research, Blood and Marrow Transplantation Clinical Lead, CAR-T Cell Program, Associate Professor of Medicine at Columbia University Medical Center
    Sunday, December 11th
    (60-Minute Group Meetings - Live Event Only, No Transcript)
    10:00 AM ET (9:00 AM CT) - Ravi Vij // Virtual
    Myelomas | Professor of Medicine at Washington University, St. Louis
    10:00 AM ET (9:00 AM CT) - Biree Andemariam // In-Person
    Sickle Cell | Associate Professor of Medicine at University of Connecticut Health Center
    11:00 AM ET (10:00 AM CT) - Rory Shallis // In-Person
    Leukemia and Myeloid Malignancies | Assistant Professor at Yale University School Of Medicine
    11:00 AM ET (10:00 AM CT) - Joshua Brody // Virtual
    Lymphomas | Associate Professor in Hematology and Medical Oncology & Director of the Lymphoma Immunotherapy Program at Mount Sinai Medical Center Inc.
    12:00 PM ET (11:00 AM CT) - Marc Braunstein // Virtual
    Multiple Myeloma | Clinical Assistant Professor of Medicine at NYU Langone Hospitals
    12:00 PM ET (11:00 AM CT) - Joshua Sasine // Virtual
    Cell Therapies | Assistant Professor of Medicine, Founder and Co-Director of the CAR T Program at Cedars-Sinai Health System
    1:00 PM ET (12:00 PM CT) - Richard Drachtman // In-Person
    Non-Malignant Hematology | Clinical Section Chief, Pediatric Hematology/Oncology at Rutgers Cancer Institute of New Jersey
    1:00 PM ET (12:00 PM CT) - Uwe Platzbecker // In-Person
    AML & MDS | Director Hematology and Cellular Therapy at Universität Leipzig
    2:00 PM ET (1:00 PM CT) - Hongtao Liu // In-Person
    Leukemias |Associate Professor of Medicine at The University of Chicago
    2:00 PM ET (1:00 PM CT) - Patrick McGann // In-Person
    Sickle Cell | Director at Hasbro Childrens Hospital
    3:00 PM ET (2:00 PM CT) - Srdan Verstovsek // Virtual
    Myeloproliferative Neoplasms (MPNs) | Professor; Director, Hanns A. Pielenz Clinical Research Center; Chief, Section for Myeloproliferative Neoplasms, Department of Leukemia at The University of Texas M. D. Anderson Cancer Center
    3:00 PM ET (2:00 PM CT) - Matthew Frigault // In-Person
    Cell Therapies | Assistant Professor at Harvard Medical School
    4:00 PM ET (3:00 PM CT) - Prithviraj Bose // Virtual
    Leukemias | MPNs | Associate Professor at The University of Texas M. D. Anderson Cancer Center
    4:00 PM ET (3:00 PM CT) - Jonathan Yen // In-Person
    Sickle Cell | Director of Therapeutic Cell and Gene Engineering Lab at St. Jude Children's Research Hospital Inc.
    Monday, December 12th
    (60-Minute Group Meetings - Live Event Only, No Transcript)
    10:00 AM ET (9:00 AM CT) - Zachariah DeFilipp // In-Person
    Leukemias and GvHD | Director, Blood and Marrow Transplant (BMT) Clinical Research, Massachusetts General Hospital at The General Hospital Corporation
    11:00 AM ET (10:00 AM CT) - Mathias Witzens Harig // In-Person
    AdvSM | Professor and Medical Doctor at Heidelberg University Hospital
    11:15 AM ET (10:15 AM CT) - Andrew Kuykendall // In-Person
    Myeloproliferative Neoplasms (MPNs) | Assistant Professor at USF Health
    12:00 PM ET (11:00 AM CT) - Jae Park // In-Person
    Cell Therapy | Attending Physician at Memorial Sloan Kettering Cancer Center
    1:00 PM ET (12:00 PM CT) - Nam Dang // Virtual
    Lymphomas | Professor of Medicine-Deputy Chief of the Division of Hematology/Oncology at University of Florida
    1:00 PM ET (12:00 PM CT) - Matthew Frigault // Virtual
    Cell Therapies | Assistant Professor at Harvard Medical School
    2:00 PM ET (1:00 PM CT) - Koichi Takahashi // Virtual
    Leukemias | Hematologic Oncologist at The University of Texas M. D. Anderson Cancer Center
    2:00 PM ET (1:00 PM CT) - Kevin Kuo // In-Person
    SCD, B-thal, and PKD | Assistant Professor at Faculty of Medicine, University of Toronto
    3:00 PM ET (2:00 PM CT) - Saurabh Dahiya // In-Person
    Leukemias and Lymphomas | Director, Cancer Cell Therapy at Stanford University
    3:00 PM ET (2:00 PM CT) - Matthew Matasar // Virtual
    Lymphomas | Chief of Medical Oncology of MSK-Bergen at American Society Of Hematology
    4:00 PM ET (3:00 PM CT) - Thynn Thynn Yee // Virtual
    Haemophilia | Consultant Hematologist at Royal Free London NHS Foundation Trust
    5:00 PM ET (4:00 PM CT) - Akshay Sharma // Virtual
    Non-Malignant Hematology and Cell Therapies | Instructor and Research Associate at St. Jude Children's Research Hospital Inc.
    Tuesday, December 13th
    (60-Minute Group Meetings - Live Event Only, No Transcript)
    10:00 AM ET (9:00 AM CT) - Thomas Leblanc // Virtual
    Leukemias | Associate Professor at Duke University Health System Inc.
    11:00 AM ET (10:00 AM CT) - Vivien Sheehan // Virtual
    Sickle Cell | Director of Translational Sickle Cell Research, Associate Professor of Pediatrics at Emory University
    12:00 PM ET (11:00 AM CT) - Ben Samelson-Jones // Virtual
    Hemophilia | Assistant Professor of Pediatrics at University of Pennsylvania

     

    Group meetings will not be recorded and transcripts will not be available after the event.

    For more details on our ASH events, please email Alyssa Vozza at avozza@guidepoint.com.

    Related Teleconferences

    DECEMBER 14 | 3:00 PM ET
    ASH 2022: Advanced Systemic Mastocytosis — A Discussion on Cogent’s Bezuclastinib With Dr. Prithviraj Bose
    Assistant Professor, University of Texas MD Anderson Cancer Center
    SIGN UP
    DECEMBER 14 | 1:00 PM ET
    ASH 2022: Arcellx- Phase I CART-ddBCMA New Clinical Data
    Assistant Professor, Division of Medical Oncology, University Of Washington Medical Center
    SIGN UP
    DECEMBER 12 | 10:00 AM ET
    ASH 2022: Adicet Bio- A Discussion on the Phase I ADI-001 Updates
    Professor of Medicine-Deputy Chief of the Division of Hematology/Oncology, University of Florida
    SIGN UP
    NOVEMBER 18 | 11:00 AM ET
    Pre-ASH 2022: Cilta-Cel Check-In and Abstract Reviews
    Associate Professor, University of Texas MD Anderson Cancer Center
    SIGN UP
    NOVEMBER 16 | 1:00 PM ET
    Pre-ASH 2022: The Novel CD19 CAR-T Landscape
    Director of Cancer Cell Therapy, Stanford University
    SIGN UP
    NOVEMBER 15
    Pre-ASH 2022: Legend, BeiGene, I-Mab, JW Therapeutics, CARsgen, and More — Evaluating China Biotech’s I/O and Cutting-Edge Developments on Stage
    President, CSO, and Acting CEO, Aleta Biotherapeutics
    REQUEST
    NOVEMBER 15
    Pre-ASH 2022: The NK Cell Therapy Landscape
    Vice Chair for Cellular Therapies, Roswell Park Comprehensive Cancer Center
    REQUEST
    NOVEMBER 15
    Pre-ASH 2022: The Novel BCMA CAR-T Landscape
    Deputy Director, Livestrong Cancer Institutes, Dell Medical School, University of Texas at Austin
    REQUEST
    NOVEMBER 15
    ASH 2022: GPRC5D Updates in Multiple Myeloma
    Clinical Assistant Professor of Medicine, NYU Winthrop Hospital and NYU Long Island School of Medicine
    REQUEST
    NOVEMBER 14
    Pre-ASH 2022 Abstract Review: Nurix Therapeutics — BTK Degrader in CLL
    Oncologist, Hematologist, and Director of the Cancer Center, Davis Health System
    REQUEST
    NOVEMBER 11
    ASH 2022: MPN Updates — Polycythemia Vera, Essential Thrombocythemia, and Systemic Mastocytosis With Dr. Srdan Verstovsek
    Professor of Medicine and Hematologist-Oncologist, The University of Texas MD Anderson Cancer Center
    REQUEST
    NOVEMBER 11
    Pre-ASH 2022: ADC Therapeutics — An Overview of the Company’s Pipeline Post-3Q22 Update
    Consultant Haematologist, Royal Sussex County Hospital
    REQUEST
    NOVEMBER 11
    ASH 2022: Blueprint Medicine — Allergist Perspective on Indolent Systemic Mastocytosis Prospects for Ayvakit Ahead of PIONEER Late-Breaker
    Partner, Pikes Peak Allergy & Asthma
    REQUEST
    NOVEMBER 11
    Pre-ASH 2022: Fate Therapeutics — Interim Data From FT819 Abstract Review With Dr. Nam Dang
    Professor of Medicine and Deputy Chief of the Division of Hematology & Oncology, University of Florida
    REQUEST
    NOVEMBER 10
    Pre-ASH 2022: Exa-cel Abstract Overview
    Director of the Pediatric and Adult Sickle Cell and Hemoglobinopathy Program, Hasbro Children’s Hospital
    REQUEST
    NOVEMBER 10
    Pre-ASH 2022: Arcellx and Gracell Biotechnologies — Next-Generation Auto CAR-T Abstract Reviews With Dr. Ravi Vij
    Professor of Medicine, Washington University in St. Louis
    REQUEST
    NOVEMBER 10
    Pre-ASH 2022: Allogene Therapeutics — ALLO-715 Abstract Review With Dr. Rahul Banerjee
    Assistant Professor of Medical Oncology, University Of Washington Medical Center
    REQUEST
    NOVEMBER 10
    Pre-ASH 2022: Gamma-Delta T-Cell Updates — Adicet Bio Abstract Review With Dr. Joshua Sasine
    Assistant Professor of Medicine and Founder & Co-Director of the CAR-T Program, Cedars-Sinai Health System
    REQUEST
    NOVEMBER 7
    Pre-ASH 2022: Hematologist Perspectives — Bezuclastinib for Advanced Systemic Mastocytosis Abstract Review
    Assistant Professor, University of South Florida Morsani College of Medicine
    REQUEST
    NOVEMBER 7
    Pre-ASH 2022: Allergist Perspectives — Bezuclastinib for Advanced Systemic Mastocytosis Abstract Review
    Program Director, Scripps Clinic Medical Group Inc.
    REQUEST
    NOVEMBER 4
    ASH 2022 — Menin Inhibitors Ziftomenib and Revumenib Abstract Reviews and Presentation Expectations With Dr. David Sallman, MD
    Assistant Member, Department of Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute Inc.
    REQUEST
    NOVEMBER 4
    ASH 2022: Myelofibrosis Landscape (Including Vonjo Uptake) Pipeline Prospects and Key Abstract Review With Dr. Brian Mulherin, MD
    Hematologist and Oncologist, Hematology Oncology of Indiana
    REQUEST
    NOVEMBER 4
    ASH 2022: DLBCL Landscape, Pipeline and Key Abstract Reviews With Dr. Nam Dang MD, PhD
    Professor of Medicine-Deputy Chief of the Division of Hematology/Oncology, University of Florida
    REQUEST